Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials



O'Neil, Patrick M, Aroda, Vanita R, Astrup, Arne, Kushner, Robert, Lau, David CW, Wadden, Thomas A, Brett, Jason, Cancino, Ana-Paula, Wilding, John PH ORCID: 0000-0003-2839-8404 and Adiposity, Satiety Clinical
(2017) Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. DIABETES OBESITY & METABOLISM, 19 (11). 1529 - 1536.

[img] Text
Neuro safety manuscript resubmit_clean.doc - Accepted Version

Download (395kB)
Item Type: Article
Uncontrolled Keywords: antiobesity drug, GLP-1 analogue, liraglutide, obesity therapy, randomized trial
Depositing User: Symplectic Admin
Date Deposited: 21 Apr 2017 13:13
Last Modified: 14 Nov 2019 21:12
DOI: 10.1111/dom.12963
Related URLs:
URI: http://livrepository.liverpool.ac.uk/id/eprint/3007070
Repository Staff Access